secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0000950170-23-011443
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50
--------------------------------------------------------------------------

- Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.
- Net proceeds to fund development programs VK2809, VK2735, VK0214 and for general R&D and working capital.
- Lead bookrunners: William Blair and Raymond James; co-managers: BTIG, Oppenheimer, H.C. Wainwright, Maxim, Roth, Laidlaw.
- Offering expected to close on April 3, 2023, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/0000950170-23-011443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023011443/vktx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer